cytomegalovirus
Takeda’s investigational therapy shows promise as cytomegalovirus treatment
September 25, 2019Research and Development, Sales and Marketing Takeda, cytomegalovirus, maribavir, pharma
New Phase 2 data has been released on Takeda’s investigational antiviral therapy TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection …
NICE recommends MSD’s Prevymis for CMV prevention following allogeneic haematopoietic stem cell transplant
May 31, 2019Medical Communications, Sales and Marketing MSD, NICE, Prevymis, UK, cmv, cytomegalovirus, pharma
MSD has revealed that its non-nucleoside CMV inhibitor Prevymis (letermovir) has secured recommendation from NICE, meaning it will now be …
MSD’s investigational cytomegalovirus treatment shows significant promise in Phase 3 trial
February 27, 2017Research and Development, Sales and Marketing MSD, cytomegalovirus, letermovir
MSD has lifted the curtain on strong Phase 3 results in the development of its investigational antiviral drug letermovir, showing …
Latest content
Long-acting therapies set to reshape HIV treatment market
August 21, 2026
MHRA approves Romvimza for tenosynovial giant cell tumour
August 20, 2026
